Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future. (3rd August 2017)

• Record Type: Journal Article
• Authors: Lin, Jie; Xue, Binbin; Li, Xiang; Xia, Junhui
• Is Part Of: International journal of neuroscience. Volume 127:Number 8(2017)
• Page Start: 735
• Page End: 744
• Publication Date: 2017-08-03
• Subjects: Neuromyelitis optica spectrum disorder -- monoclonal antibody -- rituximab -- tocilizumab -- eculizumab; Nervous system -- Periodicals; 612.805
• DOI: 10.1080/00207454.2016.1242587
• Languages: English
• ISSNs: 0020-7454

Abstract

ABSTRACT: Monoclonal-antibody has been used for patients with autoimmune disorders for several years, and efficacy and safety were appreciated for these patients. Neuromyelitis optica specturm disorder (NMOSD) has been defined as an autoimmune demyelination disorder of the central nervous system (CNS) with a course of relapse–remission. Treatment of prevention is important for patients with NMOSD because of the increased disability after several attacks. Multiple factors were involved in the pathogenesis of NMOSD. Currently, targeting specific factor was favored in the research into the treatment for NMOSD. Previous studies reported the efficacy and tolerance in NMOSD for drugs such as rituximab, tocilizumab, and eculizumab. The aim of this article is to review the current monoclonal therapies for NMOSD patients, and also future alternative options.